Seamless Phase I/II Adaptive Design for Oncology Trials of Molecularly Targeted Agents

Abstract

In dose-finding trials of chemotherapeutic agents, the goal of identifying the maximum tolerated dose is usually determined by considering information on toxicity only, with the assumption that the highest safe dose also provides the most promising outlook for efficacy. Trials of molecularly targeted agents challenge accepted dose-finding methods because minimal toxicity may arise over all doses under consideration and higher doses may not result in greater response. In this article, we propose a new early-phase method for trials investigating targeted agents. We provide simulation results illustrating the operating characteristics of our design.

Key words:

• Continual reassessment method
• Dose finding
• Molecularly targeted agent
• Optimal biological dose

Additional information

Funding

Funding was provided by the National Cancer Institute (K25 CA181638-01A).